Abstract
The fibrin-related markers (FRMs), including soluble fibrin (SF), d-dimer and fibrin and fibrinogen degradation products (FDP) are considered to be useful for the diagnosis of thrombosis; however, evidence for the diagnosis of thrombosis by SF is still not well established. The present study was designed to evaluate the usefulness of SF in the diagnosis of venous thromboembolism (VTE). The plasma concentrations of FRMs were measured in 551 in-patients suspected to have a VTE. The plasma levels of SF, d-dimer and FDP were significantly higher in patients with VTE than patients without VTE and those were significantly higher in patients without VTE than in healthy volunteers. In a receiver operating characteristic analysis for the diagnosis of VTE, the area under the curve was 0.950 for SF, 0.933 for FDP and 0.805 for d-dimer. The appropriate cut-off values for the diagnosis were as follows SF 5.9 μg/ml, FDP 2.1 μg/ml and d-dimer 4.8 μg/ml. To obtain a 100% negative predictive value for the diagnosis of VTE, the SF was less than 5.2 μg/ml, FDP was less than 1.3 μg/ml, and d-dimer was less than 0.5 μg/ml. Our findings suggest that the SF assay is useful for the diagnosis and exclusion of VTE.
Similar content being viewed by others
References
Wada H, Sakuragawa N. Are fibrin-related markers useful for the diagnosis of thrombosis? Semin Thromb Hemost. 2008;34:33–8. doi:10.1055/s-2008-1066021.
Wada H, Kobayashi T, Abe Y, Hatada T, Yamada N, Sudo A, et al. Elevated levels of soluble fibrin or d-dimer indicate high risk of thrombosis. J Thromb Haemost. 2006;4:1253–8. doi:10.1111/j.1538-7836.2006.01942.x.
Linkins LA, Bates SM, Ginsberg JS, Kearon C. Use of different d-dimer levels to exclude venous thromboembolism depending on clinical pretest probability. J Thromb Haemost. 2004;2:1256–60. doi:10.1111/j.1538-7836.2004.00824.x.
Le Gal G, Bounameaux H. Diagnosing pulmonary embolism: running after the decreasing prevalence of cases among suspected patients. J Thromb Haemost. 2004;2:1244–6. doi:10.1111/j.1538-7836.2004.00795.x.
Kline JA, Mitchell AM, Kabrhel C, Richman PB, Courtney DM. Clinical criteria to prevent unnecessary diagnostic testing in emergency department patients with suspected pulmonary embolism. J Thromb Haemost. 2004;2:1247–55. doi:10.1111/j.1538-7836.2004.00790.x.
Wada H, Sakuragawa N, Shiku H. Hemostatic molecular markers before onset of disseminated intravascular coagulation in leukemic patients. Semin Thromb Hemost. 1998;24:293–7.
Lehman CM, Wilson LW, Rodgers GM. Analytic validation and clinical evaluation of the STA LIATEST immunoturbidimetric d-dimer assay for the diagnosis of disseminated intravascular coagulation. Am J Clin Pathol. 2004;122:178–84. doi:10.1309/X4YN001GU51NGG9Y.
Wada H, Sase T, Matsumoto T, Kushiya F, Sakakura M, Mori Y, et al. Increased soluble fibrin in plasma from disseminated intravascular coagulation. Clin Appl Thromb Hemost. 2003;9:233–40. doi:10.1177/107602960300900308.
Tanigawa M, Wada H, Minamikawa K, Wakita Y, Nagaya S, Mori T, et al. Decreased protein C inhibitor after percutaneous transluminal coronary angioplasty in patients with acute myocardial infarction. Am J Hematol. 1995;49:1–5. doi:10.1002/ajh.2830490102.
Saito Y, Wada H, Yamamuro M, Inouue A, Shimura M, Hiyoyama K, et al. Changes of plasma hemostatic markers during percutaneous transluminal coronary angioplasty in patients with chronic coronary artery disease. Am J Hematol. 1999;61:238–42. doi:10.1002/(SICI)1096-8652(199908)61:4<238::AID-AJH3>3.0.CO;2-8.
Wada H, Kaneko T, Ohiwa M, Tanigawa M, Hayashi T, Tamaki S, Minami N, Deguchi K, Suzuki K, Nakano T, Shirakawa S. Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura. Am J Hematol. 1993;44:101–5. doi:10.1002/ajh.2830440206.
Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86:1327–30.
Heit JA, Silverstein MD, Mohr DN, Petterson TM, Lohse CM, O’Fallon WM, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost. 2001;86:452–63.
Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d’Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost. 2000;83:657–60.
Courtney DM, Kline JA. Identification of prearrest clinical factors associated with outpatient fatal pulmonary embolism. Acad Emerg Med. 2001;8:1136–42. doi:10.1111/j.1553-2712.2001.tb01129.x.
Wells PS, Anderson DR, Rodger M, Forgie M, Kearon C, Dreyer J, et al. Evaluation of d-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med. 2003;349:1227–35. doi:10.1056/NEJMoa023153.
Fedullo PF, Tapson VF. The evaluation of suspected pulmonary embolism. N Engl J Med. 2003;349:1247–55. doi:10.1056/NEJMcp035442.
Nieuwenhuizen W. A reference material for harmonization of d-dimer assays. Thromb Haemost. 1997;77:1031–3.
Dempfle CE, Zips S, Ergül H, Heene DL. The FACT study group: the fibrin assay comparison trial (FACT). Thromb Haemost. 2001;85:671–8.
Horan JT, Francis CW. Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation. Semin Thromb Helots. 2001;27:657–66. doi:10.1055/s-2001-18870.
Van der Putten RF, Glatz JF, Hermens WT. Plasma markers of activated hemostasis in the early diagnosis of acute coronary syndromes. Clin Chim Acta. 2006;371:37–54. doi:10.1016/j.cca.2006.03.005.
Brass EP, Forman WB, Edwards RV, Lindan O. Fibrin formation; the role of fibrinogen-fibrin monomer complex. Thromb Haemost. 1976;36:37–48.
Graeff H, Hafter R, von Hugo R. On soluble fibrinogen-fibrin complexes. Thromb Res. 1979;16:575–6. doi:10.1016/0049-3848(79)90106-3.
Soe G, Kohno I, Inuzuka K, Itoh Y, Matsuda M. A monoclonal antibody that recognizes a neo-antigen exposed in the E domain of fibrin monomer complexed with fibrinogen or its derivatives: Its application to the measurement of soluble fibrin in plasma. Blood. 1996;88:2109–17.
Suzuki A, Ebinuma H, Matsuo M, Miyazaki O, Yago H. The monoclonal antibody that recognize an epitope in the C-terminal region of the fibrinogen α-chain reacts with soluble fibrin and fibrin monomer generated by thrombin but not with those formed as plasmin degradation products. Thromb Res. 2007;121:377–85. doi:10.1016/j.thromres.2007.05.008.
Goldstein BJ, Mushlin AI. Use of a single thyroxine test to evaluate ambulatory medical patients for suspected hypothyroidism. J Gen Intern Med. 1987;2:20–4. doi:10.1007/BF02596245.
Hamano A, Tanaka S, Takeda Y, Umeda M, Sakata Y. A novel monoclonal antibody to fibrin monomer and soluble fibrin for the detection of soluble fibrin in plasma. Clin Chim Acta. 2002;318:25–32. doi:10.1016/S0009-8981(01)00779-3.
Nomura H, Wada H, Mizuno T, Katayama N, Abe Y, Noda M, et al. Negative predictive value of d-dimer for diagnosis of venous thromboembolism. Int J Hematol. 2008;87:250–5. Epub ahead of print.
Ota S, Wada H, Nobori T, Kobayashi T, Nishio M, Nishioka Y, et al. Diagnosis of deep vein thrombosis by plasma-soluble fibrin or d-dimer. Am J Hematol. 2005;79:274–80. doi:10.1002/ajh.20396.
Acknowledgments
This study was supported in part by research grants from the Japanese Ministry of Health, Labour and Welfare, from the Japanese Ministry of Education, Science, Sports and Culture and the Mie University COE Fund.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Tsuji, A., Wada, H., Matsumoto, T. et al. Elevated levels of soluble fibrin in patients with venous thromboembolism. Int J Hematol 88, 448–453 (2008). https://doi.org/10.1007/s12185-008-0173-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-008-0173-5